|
Session 95
Poster Abstracts
Pharmacokinetics and Children
Monday, 1-4 pm
Room: Hall A |
571
 |
Nelfinavir Pharmacokinetics with an Increased Dose during the First 2 Weeks of Life
Mark Mirochnick*1, K Nielsen-Saines2, J Pilotto3, J Pinto4, V Veloso5, D Holland6, H Watts7, J Moye7, L Mofenson7, Y Bryson2, and NICHD/HPTN 040/PACTG 1043 Protocol Team
1Boston Univ Sch of Med, MA, US; 2David Geffen Sch of Med, Univ of California, Los Angeles, US; 3Hosp Geral de Nova Iguaçu, Brazil; 4Federal Univ of Minas Gerais, Belo Horizonte, Brazil; 5Fiocruz Inst, Rio de Janeiro, Brazil; 6David Geffen Sch of Med, Univ of California, Los Angeles, US; and 7Natl Inst of Child Hlth and Human Devt, NIH, Bethesda, MD, US |
572
|
CYP2C19 Genetic Variants Affect Nelfinavir and M8 Pharmacokinetics and Virologic Response in HIV-1 infected Children Receiving HAART
Akihiko Saitoh*1, E Sarles1, E Capparelli1, F Aweeka2, A Kovacs3, S Buchett4, A Wiznia5, S Nachman6, T Fenton7, and S Spector1
1Univ of California, San Diego, US; 2Univ of California, San Francisco, US; 3Univ of Southern California, Los Angeles, US; 4Harvard Med Sch, Boston, MA, US; 5Jacobi Med Ctr, Bronx, NY, US; 6State Univ of New York at Stony Brook, US; and 7Harvard Sch of Publ Hlth, Boston, MA, US |
573
|
Lopinavir Pharmacokinetic Maturational Changes and Variability in HIV-infected Infants Beginning Kaletra Therapy at <6 Weeks of Age
Edmund Capparelli*1, J Pinto2, B Robbins1, C Alvero3, R Yogev4, P Palumbo5, J Rodman1, B Heckman6, and E Chadwick4
1St Jude Children`s Res Hosp, Memphis, TN, US; 2Federal Univ of Minas Gerais, Belo Horizonte, Brazil; 3Harvard Sch of Publ Hlth, Boston, MA, US; 4Feinberg Sch of Med, Northwestern Univ, Chicago, IL, US; 5Dartmouth Med Sch, Hanover, NH, US; and 6Frontier Sci & Tech Res Fndn, Amherst, NY, US |
574
|
Recommended Dose of Lopinavir/Ritonavir is Sub-optimal in Protease Inhibitor-experienced Children
Natella Rakhmanina*1,2, J Van Den Anker1,2, M Van Guilder3, S Soldin1,2, K Williams1, A Baghdassarian1,2, and M Neely3
1Children`s Natl Med Ctr, Washington, DC, US; 2George Washington Univ, Washington, DC, US; and 3Univ of Southern California, Los Angeles, US |
575
|
Therapeutic Drug Monitoring of Lopinavir and Saquinavir in Thai HIV-infected Children
J van der Lugt1, Torsak Bunupuradah*1, P Kosalaraska2, T Puthanakit1, C Engchanil2, W Sakornjun1, M Gorowara1, K Ruxrungtham1,3, D Burger4, and J Ananworanich1,5
1HIV Netherlands Australia Thailand Res Collaboration, Bangkok; 2Khon Kaen Univ, Thailand; 3Chulalongkorn Univ, Bangkok, Thailand; 4Radboud Univ Nijmegen Med Ctr, The Netherlands; and 5South East Asia Res Collaboration with Univ of Hawaii, Bangkok, Thailand |
576
|
Nevirapine Exposure with WHO Pediatric Weight Band Dosing--Enhanced Therapeutic Concentrations Predicted Based on Extensive International Pharmacokinetic Experience
Edmund Capparelli*1, D Kabamba2, T Cressey3,4, and D Burger5
1Univ of California, San Diego, US; 2Univ Teaching Hosp, Lusaka, Zambia; 3Harvard Sch of Publ Hlth, Prgm for HIV Prevention and Treatement, Boston, MA, US; 4Chiang Mai Univ, Thailand; and 5Radboud Univ Nijmegen Med Ctr, The Netherlands |
577
|
Nevirapine Pharmacokinetics in Thai Children Receiving either an Adult or Pediatric Fixed-dose Combination of Stavudine, Lamivudine, and Nevirapine
Kulkanya Chokephaibulkit*1, T Cressey2,3, W Prasitsuebsai1, N Vanprapar1, T Chotpityasunondh4, K Frederix5, J Kraimer6, R Yogev7, and E Capparelli8
1Siriraj Hosp, Bangkok, Thailand; 2Harvard Sch of Publ Hlth, Boston, MA, US; 3Chiang Mai Univ, Thailand; 4Queen Sirikit Natl Inst of Child Hlth, Bangkok, Thailand; 5Medicines Sans Frontieres; 6Social & Sci Systems, Silver Spring, MD, US; 7Chicago Children`s Memorial Hosp, IL, US; and 8Univ of California, San Diego, US |
578
|
Pharmacokinetics of the Next-generation NNRTI TMC125 in HIV-infected Children between 6 and 17 Years of Age
Thomas Kakuda*1, C Konigs2, C Feiterna-Sperling3, C Viscoli4, R Sinha5, I Peeters5, M Peeters5, K Janssen5, R Hoetelmans5, and K Boven1
1Tibotec, Inc, Yardley, PA, US; 2J W Goethe Univ, Frankfurt, Germany; 3Virchow-Klinikum, Berlin, Germany; 4Azienda Ospedaliera Univ San Martino, Genova, Italy; and 5Tibotec BVBA, Mechelen, Belgium |
|
